Freenome Inc

FRNM

Valor de mercado US$ 1,26 bi

BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026.

Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, blood-based alternative, with up to $700M in milestone payments and 10% royalties. Upcoming catalysts include the pivotal PROACT LUNG study for SimpleScreen Lung, which could validate the multiomics platform across multiple indications.

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SimpleScreen™ Lung, the company's investigational lung cancer screening test.

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott ​to launch it in the U.S. this fall, ‌the companies said on Monday.

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill.